Recursion Pharmaceuticals

Overview

Recursion Pharmaceuticals develops an AI-driven drug discovery and development platform, the Recursion OS, designed to accelerate the identification of new therapeutic targets and the design of optimized molecules. The platform integrates automated wet labs, machine learning models, and supercomputing to address the high failure rates and costs associated with traditional drug discovery.

Key Features

• Recursion OS — A proprietary AI drug discovery and development platform spanning target identification to clinical trial enrollment.
• Proprietary Data Generation — Automated high-throughput labs generate over 50 petabytes of biological and chemical data weekly, including phenomics, transcriptomics, proteomics, and ADME.
• Machine Learning Models — Intelligent models are trained on the generated data to identify new targets and design optimized molecules.
• BioHive-2 Supercomputer — Built in partnership with NVIDIA, this supercomputer processes the extensive datasets, ranking among the most powerful in biopharma.
• Industrialized Workflows — The platform employs automated processes for tissue culture, CRISPR at scale, cell seeding, compound management, incubation, and cell imaging.
• Strategic Partnerships — Collaborations with pharmaceutical and technology companies expand therapeutic reach and enhance the AI drug discovery platform.
• Pipeline Development — Focuses on developing first-in-class and best-in-class treatments for conditions with high unmet needs, such as aggressive cancers and rare diseases.

Who It's For

Recursion Pharmaceuticals primarily targets the pharmaceutical and biotechnology industries, specifically researchers and organizations involved in drug discovery and development. The platform is designed for entities seeking to leverage AI and automation to improve the efficiency, speed, and success rate of bringing new medicines to market.

Notable Strengths

Recursion's strength lies in its integrated approach, combining a massive proprietary dataset (over 50 petabytes) with advanced AI and supercomputing capabilities (BioHive-2). This allows for the rapid evaluation of hundreds of potential programs and the identification of hit candidates in weeks, a significant reduction compared to traditional timelines. The continuous feedback loop within the Recursion OS further enhances its performance and learning capabilities.